🇺🇸 FDA
Patent

US 12168008

Oxabicycloheptanes for modulation of immune response

granted A61KA61K2039/505A61K2039/54

Quick answer

US patent 12168008 (Oxabicycloheptanes for modulation of immune response) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Dec 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
35
CPC classes
A61K, A61K2039/505, A61K2039/54, A61K2039/545, A61K31/4525